 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12345678910111213...208209» |
- Focus V (anlotinib) / Advenchen, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab Combined With Anlotinib and Chemotherapy Neoadjuvant Therapy Resectable Stage II-III Non-Small Cell Lung Cancer (Exhibits and Posters, Hall C, 3F) - Jul 31, 2026 - Abstract #IASLCWCLC2026IASLC_WCLC_1808;
Abstract is embargoed at this time.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Neoadjuvant Adebrelimab Plus Chemotherapy Followed by Surgery for Resectable Small Cell Lung Cancer: A Multicenter Randomized Two-Cohort Study (Exhibits and Posters, Hall C, 3F) - Jul 31, 2026 - Abstract #IASLCWCLC2026IASLC_WCLC_1622;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab Plus Chemoradiotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer: A Phase 2 Trial (Exhibits and Posters, Hall C, 3F) - Jul 31, 2026 - Abstract #IASLCWCLC2026IASLC_WCLC_1591;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab Plus Apatinib for Maintenance Treament of ES-SCLC After First-Line Induction With Adebrelimab Plus Chemotherapy (CLOG2402-ADAPT) (Exhibits and Posters, Hall C, 3F) - Jul 31, 2026 - Abstract #IASLCWCLC2026IASLC_WCLC_1582;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab Combined With Chemotherapy Plus Individualized Radiotherapy for LS-SCLC (Exhibits and Posters, Hall C, 3F) - Jul 31, 2026 - Abstract #IASLCWCLC2026IASLC_WCLC_1567;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, HS-10370 / Jiangsu Hansoh Pharma
Efficacy and Safety of HS-10370 Combined With Adebrelimab and Chemotherapy in First-Line Advanced KRAS G12C-Mutated NSCLC (Auditorium, 3F) - Jul 31, 2026 - Abstract #IASLCWCLC2026IASLC_WCLC_1201;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- ||||||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Trial completion, Monotherapy: A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes (clinicaltrials.gov) - Jul 30, 2026
P3, N=884, Completed, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Abstract is embargoed at this time. Active, not recruiting --> Completed
- || recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
Trial completion, Trial completion date, Trial primary completion date: Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers (clinicaltrials.gov) - Jul 30, 2026
P1, N=49, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Nov 2025 | Trial primary completion date: Jun 2025 --> Nov 2025
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC (clinicaltrials.gov) - Jul 29, 2026
P2, N=120, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
Trial completion date, Trial primary completion date: Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer (clinicaltrials.gov) - Jul 28, 2026
P2, N=39, Recruiting, Sponsor: Women's Hospital School Of Medicine Zhejiang University
Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Nov 2025 | Trial primary completion date: Jun 2025 --> Nov 2025 Trial completion date: Dec 2031 --> Dec 2032 | Trial primary completion date: Dec 2026 --> Dec 2027
- |||| retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma, Avastin (bevacizumab) / Roche
New P2 trial: Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM (clinicaltrials.gov) - Jul 27, 2026
P2, N=60, Not yet recruiting, Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- |||| Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
Biomarker, Trial completion: A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment (clinicaltrials.gov) - Jul 27, 2026
P4, N=378, Completed, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2031 --> Dec 2032 | Trial primary completion date: Dec 2026 --> Dec 2027 Active, not recruiting --> Completed
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma
New P2 trial: Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV (clinicaltrials.gov) - Jul 24, 2026
P2, N=56, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | zeprumetostat (SHR-2554) / Treeline Biosci, Duoenda (mitoxantrone liposomal) / CSPC Pharma
New P1/2 trial: SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL) (clinicaltrials.gov) - Jul 24, 2026
P1/2, N=44, Not yet recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
- |||| HRS-5965 / Jiangsu Hengrui Pharma
Enrollment open: A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy (clinicaltrials.gov) - Jul 22, 2026
P2, N=380, Recruiting, Sponsor: Chengdu Suncadia Medicine Co., Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer (clinicaltrials.gov) - Jul 22, 2026
P2, N=43, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
P2 data, Journal: Dalpiciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer and visceral crisis: a multicenter, nonrandomized, phase 2 DARVIN trial. (Pubmed Central) - Jul 22, 2026
P2
Exploratory analyses indicated that a baseline monocyte-derived cfDNA level below 0.0581 was associated with worse OS (hazard ratio: 4.79, 95% CI: 1.05-45.47, P?=?0.0394), indicating a 'molecular crisis'. These findings support further evaluation of dalpiciclib plus ET in persons with ABC with visceral crisis (ClinicalTrials.gov: NCT05431504 ).
- | Olinvyk (oliceridine) / Trevena, Sufenta (sufentanil) / Akorn
Enrollment open: RMZ-OLI-ENDO: Remimazolam Combined With Oliceridine for Sedation in Elderly Patients Undergoing Gastrointestinal Endoscopy (clinicaltrials.gov) - Jul 21, 2026
P=N/A, N=240, Recruiting, Sponsor: Baoshan Branch, Renji Hospital, Shanghai Jiao Tong University School of Medicine
These findings support further evaluation of dalpiciclib plus ET in persons with ABC with visceral crisis (ClinicalTrials.gov: NCT05431504 ). Not yet recruiting --> Recruiting
- || GSK6582701 / GSK
Enrollment open: A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-9821 Powder for Inhalation Administered as a Single Dose in Healthy Participants and Multiple Doses in Patients With COPD (clinicaltrials.gov) - Jul 20, 2026
P1, N=48, Recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
New P3 trial: A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis (clinicaltrials.gov) - Jul 17, 2026
P3, N=382, Not yet recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
- || GSK5784283 / GSK
New P1 trial: A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283 (clinicaltrials.gov) - Jul 17, 2026
P1, N=24, Not yet recruiting, Sponsor: GlaxoSmithKline
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Hypofractionated Partial Tumor Irradiation Followed by Adebrelimab Combined with Chemotherapy as Induction Therapy before Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer () - Jul 17, 2026 - Abstract #ESMO2026ESMO_5830;
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer: A single-arm, prospective phase II trial () - Jul 17, 2026 - Abstract #ESMO2026ESMO_5816;
- AiTan (rivoceranib) / Elevar Therapeutics
Safety and Efficacy of Apatinib Combined With Irinotecan Liposome Injection in the Treatment of Recurrent or Metastatic Osteosarcoma: A Single-Arm, Open-Label, Prospective Multicenter Clinical Study () - Jul 17, 2026 - Abstract #ESMO2026ESMO_5812;
- AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Neoadjuvant long-course chemoradiotherapy (LCCRT) followed by fuzuloparib and capecitabine in locally advanced rectal cancer: Results from a phase 2 study () - Jul 17, 2026 - Abstract #ESMO2026ESMO_5682;
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Real-world effectiveness and safety of camrelizumab plus platinum and taxane as first-line treatment for advanced esophageal squamous cell carcinoma () - Jul 17, 2026 - Abstract #ESMO2026ESMO_5413;
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Preliminary results from Phase II trial of perioperative Adebrelimab combined with XELOX in resectable locally advanced gastric/gastroesophageal junction cancer (PAXGC study) () - Jul 17, 2026 - Abstract #ESMO2026ESMO_5362;
- AiTan (rivoceranib) / Elevar Therapeutics, Qibeian (iparomlimab/tuvonralimab) / Sound Biologics, Qilu Pharma
Iparomlimab and Tuvonralimab (QL1706) Combined with Apatinib and Capecitabine for the Treatment of Advanced Esophageal Squamous Cell Carcinoma (ESCC): A Single-Arm, Open-Label, Phase II Clinical Trial () - Jul 17, 2026 - Abstract #ESMO2026ESMO_5356;
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Camrelizumab plus chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: 4-year follow-up from a phase 2 trial () - Jul 17, 2026 - Abstract #ESMO2026ESMO_5349;
- ruzaltatug rezetecan (SHR-A2009) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Anti-HER3 Antibody-Drug Conjugate (ADC) SHR-A2009 plus Adebrelimab in Immunotherapy-Treated Advanced Esophageal Squamous Cell Carcinoma (ESCC): Cohort D Results from the CAP 02 Study () - Jul 17, 2026 - Abstract #ESMO2026ESMO_5340;
- retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
A Prospective, Randomized, Controlled Phase II Study of Stereotactic Body Radiotherapy (SBRT) Plus SHR-1701 Versus SBRT Alone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer () - Jul 17, 2026 - Abstract #ESMO2026ESMO_5100;
- Nubeqa (darolutamide) / Bayer, Orion Corp, AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
Clinical characteristics, drug-drug interaction risk, and outcomes of darolutamide and rezvilutamide triplet therapy in Chinese patients with metastatic hormone?sensitive prostate cancer () - Jul 17, 2026 - Abstract #ESMO2026ESMO_5090;
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Dalpiciclib combined with endocrine therapy and capecitabine in high-risk HR+/HER2- advanced breast cancer: a multicenter phase II study () - Jul 17, 2026 - Abstract #ESMO2026ESMO_4853;
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
An Open-label, Single-arm Study of Dalpiciclib in Combination with Aromatase Inhibitor (AI) and Capecitabine as Neoadjuvant Therapy for high-risk HR+/HER2- Early Breast Cancer () - Jul 17, 2026 - Abstract #ESMO2026ESMO_4852;
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
Inetetamab Combined with Pyrotinib for HER2-Positive Advanced Breast Cancer: A Multicenter Real-World Retrospective Study () - Jul 17, 2026 - Abstract #ESMO2026ESMO_4817;
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Neoadjuvant Chemotherapy plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer: A Prospective, Single-arm, Multi-center Study (NEOTORCH-BREAST05) () - Jul 17, 2026 - Abstract #ESMO2026ESMO_4809;
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
Real-World Effectiveness of Camrelizumab Plus Rivoceranib in Unresectable Hepatocellular Carcinoma () - Jul 17, 2026 - Abstract #ESMO2026ESMO_4775;
- AiTan (rivoceranib) / Elevar Therapeutics
Cannabigerol sensitizes hepatocellular carcinoma cells to rivoceranib through calcium-dependent suppression of PI3K-AKT-mTOR/E2F1 signaling () - Jul 17, 2026 - Abstract #ESMO2026ESMO_4759;
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
Transarterial chemoembolization (TACE) combined with Camrelizumab and Apatinib versus camrelizumab and apatinib in the treatment of unresectable hepatocellular carcinoma : A multicenter, open-label, randomized trial () - Jul 17, 2026 - Abstract #ESMO2026ESMO_4742;
- Avastin (bevacizumab) / Roche, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Hepatic arterial infusion chemotherapy plus adebrelimab and bevacizumab as conversion therapy for hepatocellular carcinoma: an investigator-initiated phase II study () - Jul 17, 2026 - Abstract #ESMO2026ESMO_4734;
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
A Multicenter, Randomized, Controlled Phase II Study of Camrelizumab Combined with Apatinib as Adjuvant Therapy in Patients with High Recurrence Risk After Radical Resection of Hepatocellular Carcinoma () - Jul 17, 2026 - Abstract #ESMO2026ESMO_4732;
- Zepsun (donafenib) / Suzhou Zelgen, AiRuiKa (camrelizumab) / Elevar Therapeutics
Hepatic arterial infusion chemotherapy combined with donafenib and camrelizumab in the treatment of unresectable hepatocellular carcinoma with portal vein tumor thrombus: A prospective single-arm study () - Jul 17, 2026 - Abstract #ESMO2026ESMO_4730;
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
First-Line Gemcitabine and Cisplatin Plus Camrelizumab and Apatinib in Nasopharyngeal Carcinoma with Liver Metastasis: Interim Analysis () - Jul 17, 2026 - Abstract #ESMO2026ESMO_4674;
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Liposomal irinotecan ? combined with gemcitabine, cisplatin and camrelizumab in the treatment of patients with unresectable biliary tract cancer () - Jul 17, 2026 - Abstract #ESMO2026ESMO_4106;
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
Camrelizumab Plus Apatinib Combined with Gemcitabine and Oxaliplatin (GEMOX) as First-Line Treatment for Advanced Biliary Tract Cancer (BTC): A Biomarker Exploratory Phase II Trial () - Jul 17, 2026 - Abstract #ESMO2026ESMO_4093;
- AiTan (rivoceranib) / Elevar Therapeutics
Molecular determinants of durable response to Apatinib in pulmonary metastatic osteosarcoma (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3637;
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Maintenance therapy with adebrelimab plus apatinib in extensive-stage small-cell lung cancer: a prospective, multicentre, single-arm phase II study (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3374;
- AiTan (rivoceranib) / Elevar Therapeutics
Irinotecan Liposome Plus Vincristine and Apatinib for Relapsed/Refractory Adult Rhabdomyosarcoma: An Exploratory Study (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3317;
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, HRS-4642 / Jiangsu Hengrui Pharma
Perioperative HRS-4642, Chemotherapy, and Adebrelimab in KRAS G12D-Mutant Pancreatic Cancer: Preliminary Phase 2 Results (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3105;
- HRS-4642 / Jiangsu Hengrui Pharma
HRS-4642 with dual immunotherapy and chemotherapy for advanced pancreatic cancer: Preliminary results from Arm 1 of a phase II study (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3097;